Comparative Pharmacology
Head-to-head clinical analysis: FLOVENT DISKUS 250 versus PREDNISONE INTENSOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLOVENT DISKUS 250 versus PREDNISONE INTENSOL.
FLOVENT DISKUS 250 vs PREDNISONE INTENSOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluticasone propionate is a corticosteroid with potent anti-inflammatory activity. It binds to the glucocorticoid receptor, leading to inhibition of pro-inflammatory cytokines, reduction of eosinophil recruitment, and suppression of airway hyperresponsiveness.
Prednisone is a prodrug that is converted to prednisolone, which binds to the glucocorticoid receptor, modulating gene expression to produce anti-inflammatory and immunosuppressive effects by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing cytokine production.
250 mcg inhaled orally via DISKUS twice daily (500 mcg total daily dose).
5-60 mg orally once daily or divided twice daily, titrated to response.
None Documented
None Documented
Approximately 10-12 hours (terminal elimination half-life in asthmatics).
2-4 hours (terminal) for prednisone; prednisolone half-life 2-4 hours. Clinical context: shorter than anti-inflammatory effect due to delayed receptor-mediated action.
Renal (approximately 5% as unchanged drug); fecal (majority as metabolites and unabsorbed drug).
Renal: <30% unchanged; major metabolites (prednisolone, 20-dihydroprednisolone) conjugated and excreted in urine. Fecal: <10%.
Category C
Category D/X
Corticosteroid
Corticosteroid